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Summary
Background Rivaroxaban is established for the treatment and secondary prevention of venous thromboembolism, but 
whether it is useful in patients with antiphospholipid syndrome is uncertain.
Methods This randomised, controlled, open-label, phase 2/3, non-inferiority trial, done in two UK hospitals, included 
patients with antiphospholipid syndrome who were taking warfarin for previous venous thromboembolism, with a 
target international normalised ratio of 2·5. Patients were randomly assigned 1:1 to continue with warfarin or receive 
20 mg oral rivaroxaban daily. Randomisation was done centrally, stratiﬁ ed by centre and patient type (with vs without 
systemic lupus erythematosus). The primary outcome was percentage change in endogenous thrombin potential 
(ETP) from randomisation to day 42, with non-inferiority set at less than 20% diﬀ erence from warfarin in mean 
percentage change. Analysis was by modiﬁ ed intention to treat. Other thrombin generation parameters, thrombosis, 
and bleeding were also assessed. Treatment eﬀ ect was measured as the ratio of rivaroxaban to warfarin for thrombin 
generation. This trial is registered with the ISRCTN registry, number ISRCTN68222801.
Findings Of 116 patients randomised between June 5, 2013, and Nov 11, 2014, 54 who received rivaroxaban and 56 who 
received warfarin were assessed. At day 42, ETP was higher in the rivaroxaban than in the warfarin group (geometric 
mean 1086 nmol/L per min, 95% CI 957–1233 vs 548, 484–621, treatment eﬀ ect 2·0, 95% CI 1·7–2·4, p<0·0001). 
Peak thrombin generation was lower in the rivaroxaban group (56 nmol/L, 95% CI 47–66 vs 86 nmol/L, 72–102, 
treatment eﬀ ect 0·6, 95% CI 0·5–0·8, p=0·0006). No thrombosis or major bleeding were seen. Serious adverse events 
occurred in four patients in each group.
Interpretation ETP for rivaroxaban did not reach the non-inferiority threshold, but as there was no increase in 
thrombotic risk compared with standard-intensity warfarin, this drug could be an eﬀ ective and safe alternative in 
patients with antiphospholipid syndrome and previous venous thromboembolism.
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Health Research Biomedical Research Centre.
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Introduction
Thrombotic antiphospholipid syndrome is a potentially 
fatal and devastating disorder. The mainstay for 
secondary prevention of venous thromboembolism is 
anticoagulation with warfarin or other vitamin K 
antagonists.1,2 Approximately 15% of patients with 
systemic lupus erythematosus have thrombotic 
antiphospholipid syndrome, which severely worsens 
the outlook.3 Antiphospholipid syndrome is classiﬁ ed 
as a rare disease,4 but a systematic review suggests 
that anti phospholipid antibodies are present in 10% 
of patients with deep vein thrombosis,5 which 
suggests possible underdiagnosis of antiphospholipid 
syndrome. Appropriate management of thrombotic 
antiphospholipid syndrome is crucial to minimise its 
harmful eﬀ ects.
Direct oral anticoagulants, including rivaroxaban,6 are 
licensed for the treatment and secondary prevention 
of venous thromboembolism and are established as 
therapeutic alternatives to low-molecular-weight heparins 
and vitamin K antagonists. Patients with antiphospholipid 
syndrome were probably included in phase 3 randomised 
controlled trials of direct oral anticoagulants, but, 
because antiphospholipid antibody status was not 
systematically documented in these trials, conﬁ rmation 
of the usefulness of direct oral anticoagulants in these 
patients is required.
Generation of thrombin via the tissue factor pathway is 
integral to the blood coagulation process. Markers of in-
vivo coagulation activation provide information about an 
individual’s thrombogenic potential,7  and their concen-
trations should be reduced after anticoagulation.8 
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Research in context
Evidence before this study
We searched MEDLINE and PubMed with the following phrases: 
“antiphospholipid syndrome”, “systemic lupus erythematosus”, 
“venous thromboembolism”, “new oral anticoagulants”, “novel 
oral anticoagulants”, “direct acting oral anticoagulants”, “direct 
inhibitors of coagulation”, “non-vitamin K antagonist oral 
anticoagulants”, “warfarin”, “coumadin”, “vitamin K 
antagonists”, “dabigatran”, “rivaroxaban”, “apixaban”, 
“edoxaban”, “thrombin generation”, and “in vivo coagulation 
activation markers”. Further information was also requested 
from the manufacturers of the individual direct oral 
anticoagulants. Thrombotic antiphospholipid syndrome is a 
potentially fatal and devastating disorder. Although the disorder 
is rare, antiphospholipid antibodies are thought to be present in 
10% of patients with deep vein thrombosis, suggesting possible 
underdiagnosis of thrombotic antiphospholipid syndrome. 
Warfarin and other vitamin K antagonists are the standard of 
care for the secondary prevention of venous thromboembolism 
in patients with thrombotic antiphospholipid syndrome. 
These drugs, however, can be particularly problematic in 
patients with thrombotic antiphospholipid syndrome because 
of variable sensitivity of thromboplastins to lupus anticoagulant, 
which is present in many of these patients. Consequently, the 
international normalised ratio (INR), which is used to monitor 
warfarin treatment, might not accurately reﬂ ect anticoagulation 
intensity. Two randomised controlled trials in thrombotic 
antiphospholipid syndrome have reported no beneﬁ ts with 
high-intensity versus standard-intensity warfarin in the 
prevention of recurrent thrombosis. Rivaroxaban and other 
direct oral anticoagulants are eﬀ ective and safe compared with 
warfarin for the treatment and secondary prevention of venous 
thromboembolism. Although antiphospholipid antibody status 
was not systematically documented in randomised controlled 
trials of direct oral anticoagulants, it is likely that patients with 
antiphospholipid syndrome were included. In the Rivaroxaban in 
Antiphospholipid Syndrome (RAPS) non-inferiority trial, 
therefore, we aimed to conﬁ rm the usefulness of rivaroxaban in 
secondary prevention of venous thromboembolism in patients 
with antiphospholipid syndrome.
Added value of this study
RAPS is slightly larger than the two previous randomised 
controlled trials in patient with thrombotic antiphospholipid 
syndrome, and our inclusion criteria enabled recruitment of a 
more homogeneous study population, that is, only patients 
with previous venous thromboembolism needing 
standard-intensity warfarin and none with arterial thrombosis 
related to antiphospholipid syndrome, which is not a licensed 
indication for direct oral anticoagulants. Because thrombotic 
antiphospholipid syndrome is clinically heterogeneous, the 
homogeneity of our study population maximises the clinical 
applicability of our results. Thrombin generation allows 
assessment of the anticoagulant eﬀ ects of warfarin and 
rivaroxaban despite these drugs’ diﬀ erent modes of action. 
When assessed by endogenous thrombin potential ([ETP] ie, 
the are under curve) alone, rivaroxaban was inferior to warfarin 
in terms of anticoagulation intensity, but peak thrombin 
generation favoured rivaroxaban. Warfarin aﬀ ects all thrombin 
generation parameters equally, whereas rivaroxaban mainly 
aﬀ ects the initiation and propagation phases of thrombin 
generation. Formation of the prothrombinase complex is 
delayed and lag time and time to peak thrombin generation are 
prolonged and, therefore, the ETP is greater than would be 
expected for the degree of anticoagulation. Thus, the overall 
thrombogram indicated no increase in thrombotic risk with 
rivaroxaban. This conclusion was supported by concentrations 
of in-vivo coagulation activation markers being increased in 
only a few patients in both treatment groups, and the absence 
of new thrombotic events during 6 months of treatment. 
No major bleeding episodes were noted, and rivaroxaban was 
signiﬁ cantly associated with improved quality of life. 
Additionally, we found no evidence in in-vitro studies of 
antiphospholipid antibodies interfering with the anticoagulant 
action of rivaroxaban.
Implications of all the available evidence
Rivaroxaban seems to oﬀ er an eﬀ ective, safe, and convenient 
alternative to warfarin in patients with thrombotic 
antiphospholipid syndrome who have had previous venous 
thromboembolism requiring standard-intensity warfarin therapy 
(ie, target INR 2·5, range 2·0–3·0). The RAPS ﬁ ndings are 
applicable to this group of patients due to the homogeneity of the 
study population. An alternative to warfarin would be welcomed 
by these patients and their treating clinicians, particularly because 
of issues with variable sensitivity of thromboplastins to lupus 
anticoagulant and unstable INR needing frequent and 
unpredictable anticoagulant monitoring. Warfarin is also 
associated with risks of thrombosis or bleeding due to 
underanticoagulation and overanticoagulation, respectively. 
The RAPS trial, however, was designed with a laboratory surrogate 
outcome measure that reﬂ ects the mechanisms of action of the 
interventions because the large-scale, long-term clinical trials 
needed to assess recurrent venous thromboembolism are not 
feasible in patients with antiphospholipid syndrome. The absence 
of new thrombosis or major bleeding and the low rate of clinically 
relevant bleeding indicate low risks in the subgroup of patients 
assessed and puts into context anecdotal reports in case studies 
and small case series of recurrent thrombosis after switching from 
warfarin to a direct oral anticoagulant in patients with 
antiphospholipid syndrome. The small but signiﬁ cant 
improvement in the quality of life visual analoge score seen with 
rivaroxaban in RAPS is encouraging. Further studies are needed to 
deﬁ ne the role of direct oral anticoagulants in the treatment of 
patients with antiphospholipid syndrome, including those who 
need higher-intensity anticoagulation after recurrent 
thrombotic events while they were taking standard-intensity 
anticoagulation, and those with stroke or other arterial 
thrombosis. 
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Thrombin generation triggered by tissue factor, therefore, 
seems to be a relevant marker.9 Thrombin generation acts 
as a global measure of anticoagulation and can show the 
anticoagulant eﬀ ects of warfarin and rivaroxaban despite 
these drugs having diﬀ erent modes of action on the 
coagulation mechanism. The thrombin generation curve 
is quantiﬁ ed in terms of the lag time, time to peak 
thrombin generation, peak thrombin generation, and 
endogenous thrombin potential (ETP), which is the area 
under the curve. Warfarin reduces the ETP by 30–50% of 
that before warfarin or that in normal controls.10,11 
Rivaroxaban inhibits thrombin generation in whole blood 
and platelet-rich plasma,12 and the ETP may be used as a 
measure of anticoagulation intensity.13,14
We did the Rivaroxaban in Antiphospholipid Syndrome 
(RAPS) trial to investigate whether rivaroxaban would 
provide anticoagulation non-inferior to that achieved 
with standard-intensity warfarin in patients with 
antiphospholipid syndrome and previous venous 
thromboembolism, with or without systemic lupus 
erythematosus. The study protocol has been published15 
and is available online.
Methods
Study design
RAPS was a randomised, controlled, open-label, phase 2/3, 
non-inferiority clinical trial in patients with thrombotic 
antiphospholipid syndrome who were receiving 
standard-intensity warfarin for venous thromboembolism 
(appendix p 3). We recruited patients from specialist 
haematology and rheumatology clinics at University 
College London Hospitals and Guy’s and St Thomas’ 
Hospitals NHS Foundation Trusts, London, UK. Enrolled 
patients provided informed written consent after 
discussion with a hospital study investigator or a delegate.
The trial was overseen by an independent trial steering 
committee (appendix p 5). An independent data 
monitoring committee (appendix p 5) provided oversight 
and monitored trial progress. Ethics approval was 
obtained from the University College London Hospitals 
NHS Foundation Trust research and develop ment oﬃ  ce, 
having been approved by the National Research Ethics 
Service Committee South Central-Oxford A (reference 
12/SC/0566).
Patients
Eligible patients had thrombotic antiphospholipid 
syndrome (appendix p 3)16 and at least one venous 
thrombo embolism when taking no or subtherapeutic 
anticoagulant therapy (appendix p 3), and had been 
taking standard-intensity warfarin (target international 
normalised ratio [INR] 2·5) for at least 3 months since 
the last venous thromboembolic event. Women had to be 
using adequate contraception (appendix p 3) unless they 
were post menopausal or had undergone sterilisation.
We excluded patients with previous arterial thrombotic 
events (appendix pp 3, 4) due to antiphospholipid syndrome 
or recurrent venous thromboembolism when taking 
warfarin at a therapeutic INR of 2·0–3·0 and those who 
were younger than 18 years. Other exclusion criteria were 
pregnancy or lactation; severe renal impairment (creatinine 
clearance calculated with the Cockcroft and Gault 
formula17,18 ≤29 mL/min); alanine aminotransferase more 
than twice the upper limit of normal; Child-Pugh class B or 
C cirrhosis; thrombocytopenia (platelets <75 × 10⁹/L); 
non-adherence to warfarin regimen (based on clinical 
assessment); taking azole class antifungals, protease 
inhibitors (eg, ritonavir) for HIV, strong CYP3A4 inducers 
(eg, rifampicin, phenytoin, carbamazepine, phenobarbital, 
or St John’s wort), or dronedarone; and refusal to give 
consent for the study site to inform a family doctor or 
health-care professional responsible for anticoagulation 
care about participation.
 All patients enrolled met the international consensus 
criteria for antiphospholipid syndrome,16 with testing for 
antiphospholipid antibodies done in accordance with 
national and international guidelines (appendix 
pp 6, 7).16,19,20 All patients with systemic lupus ery-
th ematosus were classiﬁ ed according to the revised 
criteria of the American College of Rheumatologists21 
and reviewed in lupus clinics by experienced clinicians, 
according to standard activity and damage assessment 
indices, although the results were not part of this study.
We did not apply any performance status criteria for 
trial entry, and all patients included in the trial were 
outpatients. We did not anticipate that mortality during 
follow-up would diﬀ er from that in the general population.
Randomisation and masking
Randomisation was performed by a web-based 
independent randomisation service (Sealed Envelope, 
London, UK) to ensure allocation concealment. The 
schedule was created using permuted blocks with a 
random block length, stratiﬁ ed by centre and patient 
type (with vs without systemic lupus erythematosus). 
Participants were randomised 1:1 to remain on standard-
intensity warfarin with target INR 2·5 (range 2·0–3·0) 
or to switch to 20 mg oral rivaroxaban once daily (or 
15 mg once daily depending on local clinical care and 
following the summary of product characteristics in 
patients with creatinine clearance 30–49 mL/min) for 
180 days (appendix pp 8, 9).6
The trial was open label to ensure optimum warfarin 
dosing, as the variable sensitivity of thromboplastins to 
lupus anticoagulant22 can lead to INR instability. This and 
other factors, such as changing medication, can necessitate 
frequent anticoagulant monitoring with unpredictable 
time intervals. Additionally, the manage ment of bleeding 
events diﬀ ers between patients receiving warfarin and 
rivaroxaban. Masking of treatment allocation was also not 
possible in the RAPS central laboratory because diﬀ erent 
tests were needed for the two anticoagulants, and samples 
taken at baseline and day 42 were tested simultaneously to 
minimise variability between assays.
See Online for appendix
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Follow-up
Trial follow-up continued for 210 days. Patients or 
clinicians could choose to stop treatment early because 
of unacceptable serious adverse events (SAEs), 
thrombotic events, any change in the patient’s condition 
that justiﬁ ed discontinuation (decided by clinician; 
included needing any drug speciﬁ ed in the exclusion 
criteria), withdrawal of consent (decided by patient), 
and pregnancy.
In patients with renal impairment, the dose of 
rivaroxaban could be modiﬁ ed if creatinine clearance 
changed. Patients receiving 20 mg rivaroxaban once daily 
could receive 15 mg if creatinine clearance changed to 
30–49 mL/min,6 and in patients receiving 15 mg daily, the 
dose could be changed to 20 mg if creatinine clearance 
changed to 50 mL/min or more. Treatment with 
rivaroxaban could also be temporarily stopped if a patient 
had a bleeding event or needed bridging anticoagulation 
for a procedure (routine or emergency).
Assessments
Venous blood was collected at baseline and day 42 with 
minimum venostasis, into 0·105 M citrate Vacutainer 
tubes (BD, Plymouth, UK). Platelet-poor plasma was 
prepared within 2 h by double centrifugation (2000 g for 
15 min at ambient temperature) and stored at –80°C. Trial 
assays were performed in the RAPS central laboratory in 
the Haemostasis Research Unit, University College 
London, London, UK. Patients taking rivaroxaban were 
asked to attend for venepuncture on day 42 2–4 h after the 
rivaroxaban dose to capture the peak for assessment of 
thrombin generation and rivaroxaban anti-Xa levels. 
Thrombin generation testing was done with the 
Calibrated Automated Thrombogram9 and PPP Reagent 
(Diagnostica Stago, Asnières sur Seine, France).23 ETP 
and peak thrombin generation results were normalised 
by use of thrombin generation test reference plasma 
(National Institute for Biological Standards, Potters Bar, 
UK) to reduce interassay variability.24 The intra-assay and 
interassay coeﬃ  cients of variation for lag time, ETP, and 
peak thrombin generation were 0·8–1·4% and 2·0–2·6%, 
respectively.
To assess in-vivo coagulation activation, we measured 
prothrombin fragment (F1.2), thrombin–antithrombin 
complex, and D-dimer concentrations.23 
Prothrombin time was assessed with PT-Fibrinogen 
HS Plus on a TOP500 (Werfen, Warrington, UK) with an 
analyser-speciﬁ c international sensitivity index. INR 
monitoring of patients assigned to continue warfarin was 
done in their usual anticoagulation clinics. Factor X 
activity was measured with an amidolytic assay (Hyphen 
Biomed, Neuville-Sur-Oise, France) on the CS-2000i 
analyser (Sysmex UK, Milton Keynes, UK).25 A previously 
established therapeutic range for amidolytic factor X of 
18–33 IU/dL, which corresponds to INR 2·0–3·0, was 
used to assess anticoagulation intensity.25 The intra-assay 
coeﬃ  cient of variation with normal plasma was 8·3%.
Rivaroxaban concentrations were measured with the 
Biophen DiXaI amidolytic anti-Xa assay (Hyphen 
BioMed) on the CS-2000i analyser.23 Intra-assay 
coeﬃ  cients of variation were 1·3% at 300 μg/L and 
8·0% at 100 μg/L. 
Antiphospholipid antibody status was assessed by the 
RAPS central laboratory at baseline, in accordance 
with national and international guidelines.16,19,20 Lupus 
anticoagulant was assessed by the dilute Russell’s viper 
venom time, using Siemens Healthcare (Marburg, 
Germany) LA1 (screening) and LA2 (conﬁ rmation) 
reagents, and the Taipan venom time-to-ecarin clotting 
time ratio (Diagnostic Reagents, Thame, UK). The 
normalised ratio cutoﬀ  value for both tests was 1·2. IgG 
or IgM antibodies against cardiolipin and β2 glycoprotein 
I (β2GPI) were measured with Quanta Lite kits (Inova 
Diagnostics, San Diego, CA, USA). Moderate to high 
positivity for antibodies against cardiolipin was deﬁ ned 
as greater than the 99th centile (ie, >20 GPLU or MPLU) 
and for antibodies against β2GPI positivity as greater 
than the 99th centile (ie, >20 SGu or SMu). Triple 
positivity was deﬁ ned as concentrations of antibodies 
against cardiolipin and β2GPI greater than the 99th 
centile and a positive test for lupus anticoagulant, in 
accordance with the international consensus criteria.16 
Safety
Reports of SAEs, serious adverse reactions, and suspected 
unexpected serious adverse reactions were reviewed by 
external, independent, medically qualiﬁ ed staﬀ . SAEs 
were graded according to the Common Terminology 
Criteria for Adverse Events (version 4.0). Clinically 
relevant and minor bleeding events across all sites were 
pseudoanonymised and reviewed by one investigator 
(DAI) to remove the potential bias of interoperator 
variation. The classiﬁ cation of bleeding events as 
clinically relevant or minor, as per the protocol (appendix 
p 10), was checked and changed if appropriate. Product-
related non-serious adverse events were to be reported if 
deemed by the investigator to have occurred due to the 
drug not working (appendix p 4).
Outcome measures
The primary outcome was the percentage change in ETP 
from randomisation to day 42 (ﬁ rst trial visit after 
randomisation). Intensity of anticoagulation was assessed 
with thrombin generation. We chose the ﬁ rst visit for 
assessment because the pharmacokinetics of rivaroxaban 
suggest that the therapeutic eﬀ ect would be stable after 
a few days of treatment (the protocol speciﬁ ed that 
rivaroxaban treatment must begin within 10 days of 
randomisation) and there would be no residual eﬀ ect 
from warfarin on the ETP because the maximum 
biological half-life of the vitamin-K-dependent coagulation 
factors is 72 h.26
Secondary outcomes for eﬃ  cacy were the occurrence of 
thromboembolism up to day 210 after randomisation, 
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whether these were venous thromboembolism alone or 
a composite of venous thromboembolism and other 
thrombotic events (appendix pp 3, 4), thrombin generation 
(lag time, time to peak thrombin generation, peak 
thrombin generation, and ETP) at baseline and on day 42, 
and markers of in-vivo coagulation activation at baseline 
and day 42. Secondary outcomes for safety were SAEs and 
bleeding events from baseline to day 210. Other secondary 
outcomes were adherence to treatment, assessed by 
laboratory testing of INR and amidolytic factor X for 
warfarin and anti-factor Xa rivaroxaban level for 
rivaroxaban, both at day 42; percentage of time between 
baseline and day 180 in the therapeutic range for warfarin; 
and quality of life, assessed with the ﬁ ve-level version of 
EuroQol-5D (EQ-5D-5L) at baseline and day 42.
Statistical analysis
We set the threshold for non-inferiority of rivaroxaban 
for the primary outcome at less than 20% diﬀ erence 
from warfarin in the mean percentage change. This limit 
was based on variability of test performance between 
centres27 and clinical relevance. We calculated that if 
there were truly no diﬀ erence between groups in the 
mean percentage change in ETP, we would need to enrol 
58 patients per group to ensure with 80% power that a 
two-sided 95% CI would exclude the non-inferiority 
threshold, assuming a common SD of 36%, one-sided 
signiﬁ cance level of 2·5%, and 12% of patients who were 
not assessable for the primary outcome.
Analyses were done according to a prespeciﬁ ed statistical 
analysis plan (appendix pp 11–21) except for an exploratory 
post-hoc subgroup analysis for interactions between the 
eﬀ ects of rivaroxaban and lupus anticoagulant positivity at 
baseline for any thrombin generation parameter (appendix 
pp 22, 23). We used a modiﬁ ed intention-to-treat approach 
to include all randomised patients with assessable data in 
all analyses. Descriptive statistics were used to summarise 
patients’ demographic, clinical, and other outcomes. We 
assessed the primary outcome with a regression model to 
estimate the diﬀ erence in log-transformed ETP between 
rivaroxaban and warfarin at day 42, with a two-sided 
95% CI, adjusted for stratiﬁ cation variables and baseline 
ETP. Estimates and 95% CIs on the log scale were 
Figure 1: Trial proﬁ le
LLOD=lower limit of detection.
949 patients assessed for eligibility
833 patients excluded
680 not eligible
153 eligible but not recruited
116 patients randomised
57 assigned rivaroxaban 59 assigned continued standard 
intensity warfarin
3 patients excluded
3 results <LLOD at 
baseline
3 patients excluded
1 results <LLOD at 
baseline and day 42
1 results <LLOD at 
day 42
1 withdrew before 
day 42
54 included in analysis of primary 
 outcome
56 included in analysis of primary 
 outcome
Rivaroxaban (n=57) Warfarin (n=59)
Demographics
Mean (SD) age (years) 47 (17) 50 (14)
Women 42 (74%) 42 (71%)
Men 15 (26%) 17 (29%)
Mean (SD) BMI (kg/m²) 28 (6) 30 (6)
Stratiﬁ cation variables
SLE 11 (19%) 11 (19%)
Sites
University College London Hospital 23 (40%) 25 (42%)
Guy’s and St Thomas’ Hospitals 34 (60%) 34 (58%)
Rivaroxaban dose
20 mg once daily 55 (96%) N/A
15 mg once daily* 2 (4%) N/A
Laboratory data
Haemoglobin (g/L) 130 (126–135) 137 (134–140)
Platelet count (× 10⁹/L) 222 (205–240) 220 (204–237)
International normalised ratio 2·8 (2·6–2·9) 2·7 (2·5–3·0)
Creatinine clearance (mL/min) 92 (85–100) 95 (88–104)
Alanine aminotransferase (IU/L) 21 (19–24) 20 (17–22)
Thrombin generation
ETP (nmol/L per min)† 555 (497–619) 542 (469–626)
Lag time (min) 7·3 (6·4–8·2) 7·6 (6·6–8·7)
Time to peak thrombin generation (min) 10·8 (9·7–12·0) 11·7 (10·3–13·2)
Peak thrombin generation (nmol/L) 93·8 (78·8–111·7) 79·9 (64·9–98·2)
In-vivo coagulation activation markers
Prothrombin fragment 1·2 (pmol/L) 43·3 (38·0–49·3) 43·1 (37·5–49·6)
Thrombin–antithrombin complex (μg/L) 2·9 (2·5–3·4) 2·7 (2·6–2·9)
Median (IQR) D-dimer (mg/L FEU) 0·19 (0·19–0·25) 0·19 (0·19–0·22)
Raised in-vivo coagulation activation markers (n)
Prothrombin fragment 1·2 0 1
Thrombin–antithrombin complex 2 2
D-dimer 3 4
Any marker 5 6
Thrombotic event with no or subtherapeutic anticoagulation‡
Deep vein thrombosis§ 32 (56%) 37 (63%)
Pulmonary embolism 25 (44%) 22 (37%)
Previous bleeding events while taking anticoagulation
Major 0 0
Clinically relevant 0 4 (7%)
(Table 1 continues on next page)
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back-transformed to the original scale (appendix p 24). 
This approach was also used to analyse diﬀ erences 
between treatment groups for secondary thrombin 
generation parameters (lag time, time to peak thrombin 
generation, and peak thrombin generation) in-vivo 
coagulation activation markers, and EQ-5D-5L. Fisher’s 
exact tests were used to compare proportions. Pearson’s 
correlation coeﬃ  cient, or Spearman’s rank correlation 
coeﬃ  cient were used to explore relationships between 
ETP, INR, and laboratory measures of adherence.
Values lower than the lower limits of detection for 
thrombin generation parameters and rivaroxaban 
concentrations (ie, censored values) were excluded from 
the analysis because they cannot be handled in linear 
regression models. Patients providing non-censored 
samples were not systematically diﬀ erent from those 
who did not and, therefore, we judged it was reasonable 
to assume that these were missing completely at random. 
Because the proportion of incomplete data (censored and 
missing values) for each outcome was small (5%), we did 
no imputations.
Two sensitivity analyses were planned for the primary 
outcome: a per-protocol analysis, as is recommended for 
non-inferiority trials, and tobit regression analysis to 
account for censored values (ie, those outside the assay 
limit of detection). However, neither was required as all 
patients were still taking their allocated treatments on 
day 42, and only one patient with censored values in the 
primary outcome had non-censored baseline data that 
could have contributed to the sensitivity analysis 
(appendix p 26). 
All statistical analyses were done with Stata/IC 
version 13.1. This trial is registered with the ISRCTN 
registry, number ISRCTN68222801.
Role of the funding source
Except for the University College London, which, 
represented by the Comprehensive Clinical Trials Unit at 
UCL by formal delegated authority, undertook the RAPS 
trial as a development project, none of the funders had 
involvement in the study design, data collection, data 
analysis, data interpretation, writing of the report, or 
decision to submit for publication. The corresponding 
author had full access to all the data in the study and had 
the ﬁ nal responsibility for the decision to submit for 
publication. 
Results
116 patients were recruited between June 5, 2013, and 
Nov 11, 2014 (ﬁ gure 1). The ﬁ nal day 42 visit, when 
laboratory outcomes were assessed, was on Dec 22, 2014, 
and the ﬁ nal day 210 visit, when clinical outcomes were 
assessed, was on June 8, 2015. 57 patients were assigned 
to receive rivaroxaban and 59 to receive warfarin, and all 
patients received their allocated treatments. Of these 
116 patients, six (5%) did not contribute data for the 
primary outcome. Therefore, the primary analysis 
population included 110 patients (54 in the rivaroxaban 
group and 56 in the warfarin group). Baseline 
characteristics were similar in the two groups (table 1). 
11 patients in both groups had systemic lupus 
erythematosus. Four (3%) of 116 patients had other 
autoimmune rheumatic disorders. Numbers of 
withdrawals, losses to follow-up, and missing outcome 
data, and the number and proportion of cases excluded 
from the analyses by outcome measure and treatment 
group are shown  in the appendix (pp 25–27). Measures 
of treatment exposure for the 113 patients that completed 
the trial treatment visits (day 180) are also shown 
(appendix pp 28, 29).
Thrombin generation parameters in the two groups 
were similar at baseline. At day 42, ETP was signiﬁ cantly 
higher in the rivaroxaban group than in the warfarin 
group (table 2, ﬁ gure 2). The mean percentage change in 
ETP did not reach the non-inferiority threshold. 
By contrast, lag time and time to peak thrombin 
generation were signiﬁ cantly longer and the peak 
thrombin generation was signiﬁ cantly lower in patients 
taking rivaroxaban (table 2, ﬁ gure 2). Examples of typical 
RAPS thrombograms are shown in ﬁ gure 3. The 
exploratory post-hoc subgroup analysis showed no 
signiﬁ cant interactions between the eﬀ ects of rivaroxaban 
and lupus anticoagulant positivity at baseline on thrombin 
generation (appendix pp 22, 23).
Concentrations of F1.2, thrombin–antithrombin com-
plex, D-dimer, or a combination of these, at day 42 were 
Rivaroxaban (n=57) Warfarin (n=59)
(Continued from previous page)
aPL (Miyakis categories¶)
I (excluding triple-positive aPL) 16 (28%) 19 (32%)
I (including triple-positive aPL||) 7 (12%) 12 (20%)
IIa 30 (53%) 23 (39%)
IIb 3 (5%) 1 (2%)
IIc 1 (2%) 4 (7%)
Mean (SD) percentage of time in therapeutic range 
while taking warfarin**
64 (28) 53 (24)
Mean (SD) ED-5Q-5L quality of life scores
Health utility 0·83 (0·21) 0·79 (0·24)
Health state: VAS†† 81 (16) 75 (20)
Data are number (%) or geometric mean (95% CI) unless stated otherwise. ETP=endogenous thrombin potential. 
SLE=systemic lupus erythematosus. N/A=not applicable. aPL=antiphospholipid antibodies. FEU=ﬁ brinogen equivalent 
units. ED-EQ-5L=ﬁ ve-level EuroQol-5D. VAS=visual analogue score.*Given only to patients with creatinine clearance 
30–49 mL/min. †Less than lower limit of detection in three rivaroxaban patients and one warfarin patient. ‡Recurrent 
in eight patients assigned to rivaroxaban and nine assigned to warfarin. §Rivaroxaban group: lower limb n=23, cerebral 
venous sinus n=3, subclavian and axillary vein n=1, portal vein n=1, right ventricle n=1, superior vena cava n=1, and 
retinal vein n=2; warfarin group: lower limb n=27, cerebral venous sinus n=6, axillary vein n=1, portal vein n=1, and 
retinal vein n=2. Data not collected on whether provoked or unprovoked. ¶Category I, presence of more than one aPL 
in any combination; category IIa, presence of lupus anticoagulant alone; category IIb, presence of antibodies against 
cardiolipin alone; category IIc, presence of antibodies against β2 glycoprotein I alone. ||14 rivaroxaban patients, 
19 warfarin patients; all patients tested for triple positivity at baseline, thus numbers are higher than for 
antiphospolipid syndrome-deﬁ ning aPL; before trial entry, persistence of aPL was established in all patients but triple 
positivity was not. **Only calculated if ≥3 international normalised ratio values available; two rivaroxaban patients 
and seven warfarin patients excluded. ††One missing value in warfarin group. 
Table 1: Baseline characteristics of trial participants 
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Rivaroxaban (n=57) Warfarin (n=58) Treatment eﬀ ect† (95% CI) p value
Thrombin generation at day 42
ETP (nmol/L per min) 1086 (957 to 1233) 548 (484 to 621) 2·0 (1·7 to 2·4) <0·0001
Lag time (min) 8·9 (8·1 to 9·8) 7·3 (6·7 to 8·0) 1·2 (1·1 to 1·4) 0·0052
Time to peak thrombin generation (min) 19·2 (17·7 to 20·9) 11·2 (10·3 to 12·1) 1·7 (1·5 to 1·9) <0·0001
Peak thrombin generation (nmol/L) 55·6 (46·8 to 66·1) 85·7 (72·3 to 101·5) 0·6 (0·5 to 0·8) 0·00061
In-vivo coagulation activation markers at day 42
Prothrombin fragment 1.2 (pmol/L) 93·6 (82·1 to 106·9) 45·6 (40·1 to 52·0) 2·1 (1·7 to 2·5) <0·0001
Thrombin–antithrombin complex (μg/L) 2·4 (2·3 to 2·6) 2·6 (2·5 to 2·8) 0·9 (0·9 to 1·0) 0·14
D-dimer (mg/L ﬁ brinogen equivalent units) 0·19 (0·19 to 0·23) 0·19 (0·19 to 0·20) 0 (0 to 0) 1
Raised concentrations (also raised at baseline [n])
Prothrombin fragment 1.2 (pmol/L) 2 (0) 0 N/A N/A
Thrombin–antithrombin complex (μg/L) 0 3 (1) N/A N/A
D-dimer (mg/L FEU) 2 (1) 4 (1) N/A N/A
Any marker 3 (1) 6 (2) N/A N/A
Adherence at day 42
Median (IQR) rivaroxaban (μg/L) 162 (101 to 245) N/A N/A N/A
Factor X amidolytic (IU/dL) N/A 25·3 (23·5 to 27·3) N/A N/A
International normalised ratio N/A 2·7 (2·6 to 2·9) N/A N/A
Mean (SD) time in therapeutic range at day 180 (%)‡ N/A 55 (23) N/A N/A
Mean (SE) ED-5Q-5L quality of life scores at day 180
Health utility 0·82 (0·02) 0·78 (0·02) 0·04 (–0·02 to 0·09) 0·19
Health state: VAS 80 (1·8) 73 (1·8) 6·5 (1·4 to 11·5) 0·013
New thrombotic events at day 210
Deep vein thrombosis 0 0 N/A N/A
Pulmonary embolism 0 0 N/A N/A
Arterial thrombosis 0 0 N/A N/A
Other 0 0 N/A N/A
Any combination 0 0 N/A N/A
Bleeding events at day 210 ¶
Major 0 0 N/A N/A
Clinically relevant 3 (5%) 2/55 (4%) 1·7 (–5·9 to 9·3) N/A
Minor 10 (18%) 8/55 (15%) 3·0 (–10·5 to 16·5) N/A
Unclassiﬁ ed, insuﬃ  cient information 1 (2%) 0 1·8 (–1·7 to 5·3) N/A
Site of bleed§
Intracranial 1|| 0 N/A N/A
Skin (bruise) 3 0 N/A N/A
Oral 0 1 N/A N/A
Nasal 5 3 N/A N/A
Vaginal 1 0 N/A N/A
Rectal 0 3 N/A N/A
Lower ureteric 1 0 N/A N/A
Other 9 7 N/A N/A
Adverse events at day 210¶
SAE** 4 (7%) 3/55 (5%) 1·5 (–7·5 to 10·5) N/A
SAR 0 1/55 (2%) –1·8 (–5·3 to 1·7) N/A
SUSAR 0 0 N/A N/A
Data for the treatment groups are number (%) or geometric mean (95% CI) unless stated otherwise. ETP=endogenous thrombin potential. FEU=ﬁ brinogen equivalent units. 
N/A=not applicable. ED-EQ-5L=ﬁ ve-level EuroQol-5D. VAS=visual analogue score. SAE=serious adverse events. SAR=serious adverse reactions. SUSAR=suspected unexpected 
serious adverse reaction. *Except for one patient who withdrew before day 42 in the warfarin group. †Estimated as ratio of rivaroxaban to warfarin for thrombin generation 
and as the diﬀ erence between treatments (rivaroxaban–warfarin) for other outcomes. Regression models are adjusted for stratiﬁ cation variables and baseline values of each 
variable. ‡Includes only patients with at least three international normalised ratio measurements. §Includes patients with bleeding episodes at more than one site; only most 
severe reported here. ¶Four patients (two withdrawals, one lost to follow-up, and one death) in the warfarin group did not reach day 210. ||Not judged to be related to 
treatment; the event pre-dated the trial. **SAE grades are described in the main text.
Table 2: Results from regression models of thrombin generation parameters, in-vivo coagulation activation markers, and quality of life, adherence, and 
clinical and safety measures in all patients assigned treatment*
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raised above the normal range in three (5%) of 
57 patients taking rivaroxaban and six (10%) of 58 taking 
warfarin. Of these, one and two, respectively, also had 
raised in-vivo coagulation activation markers at baseline.
Peak rivaroxaban concentrations in plasma at day 42 
were at least 160 μg/L in 29 (51%) of 57 patients 
(>360 μg/L in three) and correlated negatively with ETP 
(rs=–0·5, 95% CI –0⋅7 to –0⋅2). Among the 28 patients 
with concentrations lower than 160 μg/L, eight were 
between 50 and 100 μg/L, and six were lower than the 
lower limit of detection of 50 μg/L. Blood samples for 
measurement were taken at 2–4 h after treatment in 39 
(70%) of 56 patients, and within 6 h in all except four 
patients (range 8–24 h).
Amidolytic factor X in patients taking warfarin 
correlated positively with ETP at day 42 (r=0·5, 95% CI 
0·3–0·7). Correlations between INR and ETP were 
negative in the rivaroxaban and warfarin groups at 
baseline, and for the warfarin group at day 42 (r=–0·5, 
95% CI –0·7 to –0·3 at both baseline and day 42). The 
percentage of time in the therapeutic range for patients 
taking warfarin was similar at baseline (table 1) and 
day 180 (table 2).
No thrombotic events were seen in patients in either 
group during 6 months of taking treatment. No patients 
required dose reductions or discontinuation of the 
allocated intervention because of drug-related toxic 
eﬀ ects. No major bleeding events were reported in either 
group up to day 210 (table 2). The numbers of other 
safety events (SAEs and clinically relevant or minor 
bleeding events) did not diﬀ er between groups.
Four SAEs were reported in patients taking rivaroxaban. 
Two were judged to be unrelated to the trial drug. The 
ﬁ rst was an intracranial haemorrhage that pre-dated the 
trial and was detected incidentally on brain imaging 
without any clinical or imaging indications of new or 
recurrent bleeding (grade 1). The second was an episode 
of abdominal pain, vomiting, arthralgia, and myalgia 
(grade 2). The other two SAEs were deemed unlikely to 
be related to the trial drug. The ﬁ rst of these was a 
suspected deep vein thrombosis at day 176, identiﬁ ed 
after the patient presented with leg pain and swelling on 
a background of chronic post-thrombotic lower limb 
swelling following a previous femoral deep vein 
thrombosis. A lower limb venous doppler scan showed 
changes related to the previous femoral vein deep vein 
thrombosis but no new thrombosis. Rivaroboxan was 
stopped while the patient received treatment with 
therapeutic dose low-molecular-weight heparin, then 
restarted (grade 2). This episode was reported as an SAE 
because of the potential seriousness of the situation. The 
second of these SAEs was intestinal perforation (grade 4).
Four SAEs were reported in patients taking warfarin, 
three of which were judged to be unrelated to the trial 
drug: one patient had an acute exacerbation of asthma 
associated with an upper respiratory tract infection 
(grade 3), one had sepsis (grade 4), and one developed 
Figure 2: Thrombin generation parameters at baseline (left) and day 42 (right)
Solid lines indicate medians, dotted lines indicate limits of normal ranges. NR=normal range. Warfarin 
(W)=patients receiving warfarin at baseline who continued taking warfarin after randomisation. Warfarin 
(R)=patients receiving warfarin at baseline who were switched to rivaroxaban at randomisation.




























































































NR 2·85–5·29 NR 2·85–5·29
NR 5·0–9·1 NR 5·0–9·1
NR 173–353 NR 173–353
NR 1308–2291 NR 1308–2291
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high-grade non-Hodgkin lymphoma stage IVB and 
subsequently died. The fourth patient had clinically 
relevant haemorrhoidal haemorrhage that was deemed 
probably to have been related to warfarin (grade 3 severe 
adverse reaction). No suspected unexpected serious 
adverse reactions were reported. There were no 
treatment-related deaths.
EQ-5D-5L health utility scores did not diﬀ er between 
groups (mean diﬀ erence 0·04, 95% CI –0·02 to 0·09, 
p=0·19; table 2). A small diﬀ erence was seen between 
groups in the visual analogue health score, favouring the 
rivaroxaban group (mean diﬀ erence 6·5, 95% CI 
1·4–11·5, p=0·013).
Discussion
When anticoagulation intensity was assessed by 
percentage change in ETP alone, rivaroxaban was inferior 
to warfarin in patients with antiphospholipid syndrome 
and previous venous thromboembolism. However, peak 
thrombin generation was lower with rivaroxaban and, 
therefore, the overall thrombogram indicated no 
diﬀ erence in thrombotic risk. This conclusion is 
supported by in-vivo coagulation activation marker 
concentrations being raised in only a few patients in both 
treatment groups. Additionally, no new thrombotic 
events were seen during 6 months of treatment. No 
patients had major bleeds, and the frequencies of 
clinically relevant and minor bleeding were similar in the 
two groups. Quality of life, as measured with EQ-5D-5L 
visual analogue scores, was signiﬁ cantly better in the 
rivaroxaban group than in the warfarin group.
Rivaroxaban and warfarin both inhibit thrombin 
generation in patients with venous thromboembolism 
who do not have antiphospholipid syndrome,23 indicating 
eﬀ ective anticoagulation. Inhibition of thrombin 
generation, which indicates eﬀ ective anticoagulation, has 
also been shown in patients with antiphospholipid 
syndrome when taking warfarin.25 However, the 
mechanism of inhibition of thrombin generation diﬀ ers 
for the two agents: warfarin reduces functional levels of 
vitamin-K-dependent coagulation factors, whereas 
rivaroxaban directly inhibits factor Xa through speciﬁ c 
binding to its active site.28,29 Warfarin, therefore, aﬀ ects all 
phases of thrombin generation equally, whereas 
rivaroxaban mainly aﬀ ects the initiation and propagation 
of thrombin generation, leading to a delay in formation 
of the prothrombinase complex.30 As a result, the 
thrombin generation curve becomes protracted, which in 
turn lengthens the lag time and time to peak thrombin 
generation,23,30 and leads to greater ETP than would be 
expected for the degree of anticoagulation.23
The diﬀ erential eﬀ ects of warfarin and rivaroxaban 
were reﬂ ected in the treatment eﬀ ects in this study. On 
average, in patients who switched from warfarin to 
rivaroxaban, ETP increased by 100% and time to peak 
thrombin generation by 70%, whereas peak thrombin 
generation decreased by 40%. The higher ETP associated 
with rivaroxaban can be explained by altered reaction 
kinetics that do not aﬀ ect thrombotic risk. This 
conclusion reﬂ ects the clinical ﬁ ndings in the phase 3 
randomised controlled trials of direct oral anti-
coagulants,6 which are likely to have included patients 
with antiphospholipid syndrome.5 
The ﬁ ndings for ETP and peak thrombin generation in 
RAPS patients at day 42 can be attributed to anticoagulation 
rather than antiphospholipid antibodies. Indeed, in vitro, 
the eﬀ ects of antiphospholipid antibodies on thrombin 
generation are limited to prolongation of lag time and 
time to peak thrombin generation.31 Our exploratory post-
hoc analysis showed no signiﬁ cant interactions between 
the eﬀ ects of rivaroxaban and lupus anticoagulant 
positivity on thrombin generation. Antiphospholipid 
antibodies might interfere with the anticoagulant action 
of direct oral anticoagulants, but we have shown no eﬀ ect 
with rivaroxaban in in-vitro studies.31
Figure 3: Thrombograms for median (25th and 7th percentiles) ETP values in 
RAPS, compared with a typical normal control value
(A) Patients taking warfarin. (B) Patients taking rivaroxaban. ETP=endogenous 
thrombin potential. RAPS=the Rivaroxaban in Antiphospholipid Syndrome trial.
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A limitation of RAPS is that it was not designed to 
conﬁ rm clinical eﬃ  cacy and long-term safety. Rather, 
the trial was designed with a laboratory surrogate 
outcome measure to assess the mechanism of action of 
the interventions in these patients. A trial with a primary 
endpoint of recurrent thrombosis would require a 
sample of several thousand patients, which is unfeasible 
for patients with thrombotic antiphospholipid syn-
drome, and a much longer follow-up period. There was 
an intended selection bias because we excluded patients 
who had had venous thromboembolism and developed 
recurrent events while taking standard-intensity anti-
coagulation (ie, needing higher-intensity anti coagul-
ation) and those with arterial events. Thus, our cohort 
seemed to have antiphospholipid antibodies that caused 
clinical disease at the less aggressive end of the range 
seen in patients with thrombotic antiphospholipid 
syndrome. Nevertheless, limiting the selection of 
patients to those with thrombotic antiphospholipid 
syndrome and previous venous thromboembolism 
leading to treatment with standard intensity warfarin 
ensured a clinically homogeneous study population 
which is in contrast to two previous, slightly smaller, 
randomised controlled trials.32,33 This feature is an 
important strength of RAPS. Thrombotic antiphospho-
lipid syndrome is clinically heterogeneous, with the risk 
of recurrent thrombosis and intensity of anticoagulation 
being dependent on the clinical phenotype.2 Thus, trials, 
such as RAPS, that involve clinically homogeneous 
thrombotic antiphospho lipid syndrome populations, 
maximise clinical applicability for subgroups of patients. 
We caution, therefore, that our results are not applicable 
to patients with antiphospholipid syndrome and venous 
thrombo embolism who need greater than standard-
intensity anticoagulation or with stroke or other arterial 
thrombosis.
Direct oral anticoagulants have several advantages 
compared with warfarin. They avoid the need for 
routine anticoagulation monitoring, which is 
particularly relevant to antiphospholipid syndrome 
patients because thromboplastins have variable 
sensitivity to lupus anticoagulants and, therefore, the 
INR might not accurately reﬂ ect anticoagulation 
intensity.22 If INR instability develops, frequent 
anticoagulant monitoring will be needed with 
unpredictable time intervals, and the risk of thrombosis 
or bleeding will be increased due, respectively, to 
undercoagulation or overcoagulation. The percentage 
of time in the therapeutic range for patients in the 
RAPS warfarin group was only 55% up to day 180. This 
ﬁ nding highlights that the predictable anticoagulant 
eﬀ ect of rivaroxaban oﬀ ers a potential advantage in 
antiphospholipid syndrome patients, but eﬃ  cacy is 
dependent upon adherence to the treatment regimen. 
Unlike treatment with warfarin, where anticoagulation 
is constant, rivaroxaban leads to peaks and troughs. No 
range of therapeutic rivaroxaban concentrations have 
been deﬁ ned for clinical use. Population pharma-
cokinetics indicate that peak rivaroxaban concentrations 
are in the range 160–360 μg/L.34 29 (51%) of 57 RAPS 
patients had peak therapeutic concentrations of at least 
160 μg/L, and three of these had concentrations greater 
than 360 μg/L. Six (11%) patients had peak 
concentrations lower than 50 μg/L and were possibly 
non-adherent.
The absence of new thrombotic events during 6 months 
of treatment in RAPS justiﬁ es our selection of this 
subgroup of patients with antiphospholipid syndrome 
and puts into context anecdotal case reports and ﬁ ndings 
in small case series of recurrent thrombosis after 
switching patients from warfarin to a direct oral 
anticoagulant. Of note, 28% of patients in RAPS had 
triple positivity for lupus anticoagulant and antibodies 
against cardiolipin and β2GPI at baseline and, therefore, 
had a particularly high-risk antibody proﬁ le.35
Our ﬁ ndings suggest that in patients with anti-
phospholipid syndrome who have had previous venous 
thromboembolism and need standard-intensity anti-
coagulation (ie, target INR 2·5) the overall thrombotic 
risk, based on the overall thrombogram, in-vivo 
coagulation activation markers and clinical outcomes, is 
not increased with rivaroxaban compared with that 
related to warfarin. The absence of new thrombosis or 
major bleeding and low rate of clinically relevant bleeding 
supports this conclusion. Further studies are required 
to deﬁ ne the role of direct oral anticoagulants in 
antiphospholipid syndrome patients, including those 
with venous thromboembolism who need higher-
intensity anticoagulation (ie, those without recurrent 
venous thromboembolism while taking standard-
intensity anticoagulation) or antiphospholipid syndrome 
patients with stroke or other arterial thrombosis. Overall, 
rivaroxaban seems eﬃ  cacious and safe, and might oﬀ er a 
convenient alternative to warfarin in this subgroup of 
patients with antiphospholipid syndrome.
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